{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Liu J"],"funding":["Innovative Research Group Project of the National Natural Science Foundation of China","National Natural Science Foundation of China"],"pagination":["72"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9357592"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(1)"],"pubmed_abstract":["<h4>Background</h4>The mortality of extensively drug-resistant Gram-negative (XDR GN) bacilli-induced ventilator-associated pneumonia (VAP) is extremely high. The purpose of this study was to compare the efficacy and safety of inhaled (IH) plus intravenous (IV) polymyxin B versus IV polymyxin B in XDR GN bacilli VAP patients.<h4>Methods</h4>A retrospective multi-center observational cohort study was performed at eight ICUs between January 1<sup>st</sup> 2018, and January 1<sup>st</sup> 2020 in China. Data from all patients treated with polymyxin B for a microbiologically confirmed VAP were analyzed. The primary endpoint was the clinical cure of VAP. The favorable clinical outcome, microbiological outcome, VAP-related mortality and all-cause mortality during hospitalization, and side effect"],"journal":["Annals of intensive care"],"pubmed_title":["Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case-control study."],"pmcid":["PMC9357592"],"funding_grant_id":["81971869","81873944"],"pubmed_authors":["Pan X","Wu J","Liu J","Yao J","Xiong L","Tian M","Wen Z","Xu Q","Zhang L","Zhang S","Chen D","Li W","Liu Y","Huang S","TaoWang","Teboul JL","Shao M","Du H","Chen Y","Liu F","Wu Y","Xu Y"],"additional_accession":[]},"is_claimable":false,"name":"Low-dose intravenous plus inhaled versus intravenous polymyxin B for the treatment of extensive drug-resistant Gram-negative ventilator-associated pneumonia in the critical illnesses: a multi-center matched case-control study.","description":"<h4>Background</h4>The mortality of extensively drug-resistant Gram-negative (XDR GN) bacilli-induced ventilator-associated pneumonia (VAP) is extremely high. The purpose of this study was to compare the efficacy and safety of inhaled (IH) plus intravenous (IV) polymyxin B versus IV polymyxin B in XDR GN bacilli VAP patients.<h4>Methods</h4>A retrospective multi-center observational cohort study was performed at eight ICUs between January 1<sup>st</sup> 2018, and January 1<sup>st</sup> 2020 in China. Data from all patients treated with polymyxin B for a microbiologically confirmed VAP were analyzed. The primary endpoint was the clinical cure of VAP. The favorable clinical outcome, microbiological outcome, VAP-related mortality and all-cause mortality during hospitalization, and side effect","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Aug","modification":"2026-07-14T17:37:02.893Z","creation":"2025-04-04T08:45:05.764Z"},"accession":"S-EPMC9357592","cross_references":{"pubmed":["35934730"],"doi":["10.1186/s13613-022-01033-5"]}}